Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCR102
- Development stage
- Phase 2
- Lead developer
- Nuwacell Biotechnologies
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
NCR102 is a cell therapy product based on **mesenchymal stem cells** derived from induced pluripotent stem cells (iPSC). It is being developed for the treatment of **acute graft-versus-host disease (aGVHD)**, especially in patients who are steroid-refractory and have failed second-line therapy. The drug is administered as an injection and is currently in Phase 1/2 clinical trials. The therapy aims to harness the immunomodulatory and anti-inflammatory properties of iPSC-derived mesenchymal stem cells to ameliorate the symptoms of aGVHD, particularly in cases with gastrointestinal involvement. NCR102 is being developed and trialed by Nuwacell Biotechnologies[5][7][9].
- Brand names
- NCR102NCR-102NCR 102
- Other names
- NCR102 injectionNCR-102 injectionNCR 102 injection
Beyond the preview
Go deeper on NCR102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCR102.